<p><b>Copyright information:</b></p><p>Taken from "An epigenetic vaccine model active in the prevention and treatment of melanoma"</p><p>http://www.translational-medicine.com/content/5/1/64</p><p>Journal of Translational Medicine 2007;5():64-64.</p><p>Published online 10 Dec 2007</p><p>PMCID:PMC2231344.</p><p></p> ) B16 cells were stained with mAb, isotype controls and annexinV after treatment with TSA and analyzed by flow cytometry for the expression of MHC class I, class II, CD80, CD86 and CD40. Isotype controls are shown as shaded peaks and heavy lines represent expression determined by specific mAb staining. Values indicated in the histograms are the percent of cells positive for the respective mAb relative to the isotype staining. The data presented here are representative of more than three independent experiments. ) Kaplan-Meier plot of B6 mice (10 in each group) inoculated with TSA-treated (500 nM for 48 h) or untreated B16 cells in the trunk. ) Durable immunity in 100% of the immune animals. Tumor-free mice, 40 days after vaccination with TSA-treated B16, were re-challenged with untreated B16 cells and observed for another 60 days. The number of tumor-free mice compared to total numbers used in each treatment group is shown in parentheses
